Wells Fargo & Company Akebia Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 99,298 shares of AKBA stock, worth $182,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
99,298
Previous 96,099
3.33%
Holding current value
$182,708
Previous $98,000
33.67%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding AKBA
# of Institutions
121Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$21.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$18.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.6 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.75 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.84 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $338M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...